Skip to main content

Year: 2023

UP Fintech Holding Limited Reports Unaudited Third Quarter 2023 Financial Results

SINGAPORE, Nov. 27, 2023 (GLOBE NEWSWIRE) — UP Fintech Holding Limited (NASDAQ: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced its unaudited financial results for the third quarter ended September 30, 2023. Mr. Wu Tianhua, Chairman and CEO of UP Fintech stated: “In the third quarter, we saw improvement in both commission income and interest-related income compared to the previous quarter. Total revenue reached US$70.1 million, representing a sequential increase of 6.2% and a year-over-year growth of 26.6%. GAAP net income attributable to UP Fintech reached US$13.2 million, representing a quarter-over-quarter slight increase of 0.5% and a significant year-over-year growth of 297.1%. Non-GAAP net income attributable to UP Fintech amounted to US$16.0 million, a...

Continue reading

Results of the Offering of Unsecured Subordinated Bonds of Bigbank AS

The public offering of Bigbank AS (Bigbank) unsecured subordinated bonds (the Offering) ended on Friday, 24 November 2023. It was the first series under Bigbank’s unsecured subordinated bond programme, which was conducted based on the base prospectus of subordinated bonds programme. Under the programme it is possible for Bigbank to raise up to 30 million euros in total. In the course of the Offering, up to 3,000 unsecured subordinated bonds, with the nominal value EUR 1,000 each, the maturity date 30 November 2033 and fixed interest rate of 8% per annum, payable quarterly, were offered by Bigbank. In case of oversubscription, Bigbank had the right to increase the volume of the Offering by up to 7,000 bonds to the total of up to 10,000 bonds. The Offering was carried out in Estonia, Latvia and Lithuania. 1847 investors participated in the...

Continue reading

The subscription period for the warrants of series TO6 starts today, November 27th, 2023

Today, November 27th, 2023, marks the commencement of the exercise period for subscription of warrants of series TO6 in Terranet AB (publ) (”Terranet” or the” Company”). The exercise period for warrants of series TO6 runs up until and including December 11th, 2023. Each warrant gives the right to subscribe for one (1) new share of series B in the Company to the price of SEK 0.054. The invested amount must be rounded up to two decimal places. For the warrants not to expire without value, the owner must actively subscribe for new shares no later than December 11th 2023, alternatively sell their warrants by the 6th of December, 2023. Please observe that certain nominees might close their application period earlier than December 11th, 2023. The letter to holders of warrants of series TO6 is available on the Company’s website www.terranet.se. Summarized...

Continue reading

26/2023・Trifork Holding AG – Weekly report on share buyback

Company announcement no. 26 / 2023Schindellegi, Switzerland – 27 November 2023 Trifork Holding AG – Weekly report on share buyback On 2 November 2023, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 November 2023 up to and including no later than 31 March 2024. For details, please see announcement no. 17 of 31 October 2023. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 15 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 232,497 treasury shares, corresponding to 1.2% of the share capital. Under the program, the following transactions have...

Continue reading

CORRECTION – Caledonia Mining Corporation Plc Results for the quarter and nine months ended September 30, 2023

The following amendment has been made to the announcement titled “Results for the quarter and nine months ended September 30, 2023” that was released on November 14, 2023 at 07:00 under RNS Number 3053T. Diluted earnings/ (loss) per share (cents) for the Quarter should be 24.0 and (6.8) for the three and nine months, rather than 14.7 and (5.5) respectively. The financial statements and management discussion and analysis, which can be found on the Company’s website, should be read accordingly. Management of the Company does not consider the error, which arose due to a clerical mistake, to be material to the financial statements taken as a whole. All other details remain unchanged. The full amended text is shown below. The shareholder call referred to in the original text took place as planned on November 16, 2023, and shareholders can find...

Continue reading

Perseus increases interest in OreCorp to 19.9%

Perth, Nov. 27, 2023 (GLOBE NEWSWIRE) — PERSEUS INCREASES INTEREST IN ORECORP TO 19.9% Perth, Western Australia/November 27, 2023/Perseus Mining Limited (ASX/TSX:PRU) (Perseus or the Company) is pleased to announce that it has increased its relevant interest in OreCorp Limited’s (OreCorp) shares from 15.03% as previously announced to 19.9%. Perseus is not currently in active discussions with OreCorp and does not intend to submit a change of control transaction in competition to the current scheme that Silvercorp Metals Inc has offered to OreCorp shareholders (initially announced to ASX on August 7, 2023 and subsequently revised on November 23, 2023) (Silvercorp Scheme). Perseus intends to vote against the Silvercorp Scheme at the OreCorp scheme meeting, which is scheduled for Friday, December 8, 2023. This announcement has been...

Continue reading

Athene Executes Block Reinsurance Transaction in Japan

HAMILTON, Bermuda, Nov. 26, 2023 (GLOBE NEWSWIRE) — Athene Holding Ltd. (“Athene”), a leading provider of retirement services products, has executed a block reinsurance transaction with FWD Life Insurance Co. Ltd., a Japanese domiciled insurer. Under the terms of the agreement, Athene will reinsure an in-force block of whole life insurance policies. In conjunction with the transaction, Athene has also entered into an agreement to retrocede the mortality risk associated with the block to Swiss Re, a leading mortality reinsurer. “We are pleased with this important extension of Athene’s franchise overseas, which demonstrates the capabilities we have developed to support the strategic objectives of insurance companies in the Japanese market,” said Grant Kvalheim, President of Athene. “We look forward to continued growth in this market...

Continue reading

Perseus acquires 15% interest in OreCorp Limited

Perth, Nov. 27, 2023 (GLOBE NEWSWIRE) — PERSEUS ACQUIRES 15.03% INTEREST IN ORECORP Perth, Western Australia/November 27, 2023/ Perseus Mining Limited (ASX/TSX:PRU) (Perseus or the Company) is pleased to announce that it has acquired a relevant interest of 15.03% in OreCorp Limited (OreCorp) shares (OreCorp Share Acquisition) as a strategic equity investment. OreCorp is an emerging mineral development company listed on the ASX under the code ORR. OreCorp’s key project is the Nyanzaga Gold Project, a pre-development project located in northwest Tanzania with a reported Probable Ore Reserve of 40.08 Mt @ 2.02 g/t gold for 2.60 million ounces of gold1. Perseus is not currently in active discussions with OreCorp and does not intend to submit a change of control transaction in competition to the current scheme that Silvercorp Metals...

Continue reading

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for orphan drug designation (ODD) and rare pediatric disease designation (RPDD) with the United States Food and Drug Administration (FDA) for its allogeneic cell therapy Revascor® (rexlemestrocel-L) in the treatment of the congenital heart disease hypoplastic left heart syndrome (HLHS). The filings were based on results from a blinded, randomized, controlled prospective trial of REVASCOR conducted at a single center in the US in 19 children with HLHS and accepted for publication in an upcoming issue of the peer reviewed The Journal of Thoracic and Cardiovascular Surgery Open (JTCVS Open).1 HLHS is a severe congenital heart disease in which...

Continue reading

Empowering Nutrition: Unveiling the Dynamics of Food Fortifying Agents Market

Chicago, Nov. 26, 2023 (GLOBE NEWSWIRE) — The global food fortifying agents market refers to the market for substances added to food to enhance its nutritional content. Food fortifying agents are used to address nutrient deficiencies and improve the overall nutritional profile of food products. These agents may include vitamins, minerals, and other nutrients that may be lacking in the diet or may be lost during food processing. The global market for food fortifying agents has been growing as consumers become more conscious of their health and nutrition. Fortified foods offer a convenient way to ensure that individuals receive essential nutrients, especially when certain nutrients are not naturally present in sufficient quantities in the diet. According to MarketsandMarkets, the global food fortifying agents market size is projected...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.